Aligos Therapeutics Inc (ALGS) Stock Price, Quote & News

Company Profile

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG-097558, a sm...

Industry: Biotechnology

Sector: Healthcare

Phone: 800 466 6059

Website: www.aligos.com

Address:

One Corporate Drive, 2nd Floor, South San Francisco, United States

ALGSmoon Jun. 29 at 6:16 PM

$ALGS gotta make sure management is taken care of. Big salaries and more stock while this probably goes all time lows in the next 60 days.

1 · Reply

ALGSmoon Jun. 26 at 1:02 AM

$ALGS paytience pays right? Or you could buy NVDA here with a high likelihood of 15% in the next month or so. To stay here, you have to belive this is going to $50 or higher in short order. How do we feel about that proposition?

0 · Reply

Buyhighsellatlow Jun. 17 at 7:49 PM

$ALGS guys, is this the pump before the dilution? Asking for a friend.

1 · Reply

CrazyStockup Jun. 16 at 4:26 PM

$ALGS What’s going on here …. ! Can’t wait for a PR which makes this move UP North !!!

0 · Reply

RocketCityRetai1 Jun. 16 at 2:04 AM

$ALGS they need to hurry up with the dilution. I want to buy before EOP2

0 · Reply

ALGSmoon Jun. 12 at 11:11 PM

$ALGS another snooze fest of a day. Now we wonder wtf we’re doing here when the capital can be working for you elsewhere. This stock is a real mental test with a shitty prize thus far for every year it’s been public. That’s why nobody wants in.

0 · Reply

10PieceTeriyaki Jun. 10 at 12:19 AM

$ALGS under 4$ no proublem here i am saying this again

0 · Reply

ALGSmoon Jun. 9 at 7:39 PM

$ALGS something is brewing. Almost out of shares to short and the stock is up 5%

0 · Reply

ALGSmoon Jun. 9 at 5:56 AM

$ALGS remember that day it hit $12 in premarket then immediately shorted to its current price? if they drop the offering without a pump, the check writers are the ones that shorted. You heard it here. Mark it.

0 · Reply

ALGSmoon Jun. 8 at 11:35 PM

$ALGS

0 · Reply

Aligos Therapeutics initiated with a Buy at Lake Street

2026-05-27T09:15:09.000Z - 5 weeks ago

Aligos Therapeutics presents data at EASL congress

May 27, 2026, 2:30 AM EDT - 5 weeks ago

Aligos Therapeutics Presents Positive Data at the EASL Congress 2026

2026-05-21T11:02:51.000Z - 6 weeks ago

Aligos Therapeutics initiated with an Overweight at Cantor Fitzgerald

2026-05-21T10:39:10.000Z - 6 weeks ago

Aligos Therapeutics initiated with an Overweight at Cantor Fitzgerald

May 13, 2026, 2:05 AM EDT - 7 weeks ago

Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026

May 7, 2026, 4:05 PM EDT - 2 months ago

Aligos Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results

May 7, 2026, 4:00 PM EDT - 2 months ago

Aligos Therapeutics Earnings release: Q1 2026

May 7, 2026, 4:00 PM EDT - 2 months ago

Aligos Therapeutics Quarterly report: Q1 2026

Apr 30, 2026, 4:05 PM EDT - 2 months ago

Aligos Therapeutics to Announce 1st Quarter 2026 Financial Results on May 7, 2026

Apr 29, 2026, 8:00 AM EDT - 2 months ago

Aligos Therapeutics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 2 months ago

Aligos Therapeutics Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 2 months ago

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-04-16T10:08:03.000Z - 2 months ago

Aligos Therapeutics signs license deal to develop pevifoscorvir in China

Apr 16, 2026, 6:00 AM EDT - 2 months ago

Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection

2026-04-14T20:18:56.000Z - 2 months ago

Aligos reports first interim analysis of B-SUPREME study, fast track designation

Apr 14, 2026, 4:05 PM EDT - 2 months ago

Aligos Therapeutics Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium in Participants with Chronic Hepatitis B Virus Infection and Grant of FDA Fast Track Designation

Apr 14, 2026, 7:00 AM EDT - 2 months ago

Aligos Therapeutics Slides: Corporate presentation

2026-03-26T13:00:14.000Z - 3 months ago

Aligos Therapeutics initiated with a Buy at WestPark Capital

Mar 19, 2026, 7:00 AM EDT - 3 months ago

Aligos Therapeutics Slides: Corporate presentation

2026-03-19T09:15:20.000Z - 3 months ago

Aligos Therapeutics assumed with a Buy at Jefferies

Mar 5, 2026, 9:30 AM EST - 4 months ago

Aligos Therapeutics Annual report: Q4 2025

Mar 5, 2026, 9:30 AM EST - 4 months ago

Aligos Therapeutics Earnings release: Q4 2025

2026-03-05T13:14:38.000Z - 4 months ago

Aligos Therapeutics reports Q4 EPS ($1.91), consensus ($2.49)

Mar 5, 2026, 8:00 AM EST - 4 months ago

Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results

Feb 26, 2026, 8:00 AM EST - 4 months ago

Aligos Therapeutics to Announce 4th Quarter 2025 Financial Results on March 5, 2026

2026-02-23T13:16:07.000Z - 4 months ago

Aligos announces data from two presentations at CROI on pevifoscorvir sodium

Feb 23, 2026, 8:00 AM EST - 4 months ago

Aligos Therapeutics Presents Positive Data at the Conference on Retroviruses and Opportunistic Infections (CROI)

2026-01-21T13:10:22.000Z - 5 months ago

Aligos Therapeutics provides update for Phase 2 study of pevifoscorvir sodium

2026-01-21T13:10:14.000Z - 5 months ago

Aligos Therapeutics announces resignation of Chief Medical Officer Achneck

Jan 21, 2026, 8:00 AM EST - 5 months ago

Aligos Therapeutics Provides Phase 2 B-SUPREME Study Progress Updates

2026-01-20T19:55:25.000Z - 5 months ago

Aligos Therapeutics management to meet virtually with Piper Sandler

2026-01-13T13:16:17.000Z - 6 months ago

Aligos Therapeutics appoints James Hassard as EVP, CCO

2026-01-07T13:21:19.000Z - 6 months ago

Aligos Therapeutics initiated with a Buy at UBS

APGE COGT IDYA IVA KOD SABS VTYX

2025-12-11T13:15:49.000Z - 7 months ago

Aligos Therapeutics presents pevifoscorvir, ALG-055009 data at HEP-DART

Dec 11, 2025, 8:00 AM EST - 7 months ago

Aligos Therapeutics Presents Positive Data at HEP-DART 2025

Nov 17, 2025, 10:00 AM EST - 8 months ago

Aligos Therapeutics Transcript: Jefferies London Healthcare Conference 2025

2025-11-10T13:37:00.000Z - 8 months ago

Aligos Therapeutics presents data from eight presentations at AASLD

Nov 10, 2025, 8:00 AM EST - 8 months ago

Aligos Therapeutics Presents Positive Data at The Liver Meeting® 2025

Nov 6, 2025, 8:30 AM EST - 8 months ago

Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results

Nov 6, 2025, 7:00 AM EST - 8 months ago

Aligos Therapeutics Quarterly report: Q3 2025

Nov 6, 2025, 7:00 AM EST - 8 months ago

Aligos Therapeutics Earnings release: Q3 2025

Nov 4, 2025, 8:30 AM EST - 8 months ago

Aligos Therapeutics to Present at Upcoming Investor Conferences

Oct 30, 2025, 8:30 AM EDT - 8 months ago

Aligos Therapeutics to Announce 3rd Quarter 2025 Financial Results on November 6, 2025

Oct 21, 2025, 7:00 AM EDT - 9 months ago

Aligos Therapeutics Transcript: H.C. Wainwright Liver Disease Virtual Conference

Oct 16, 2025, 8:30 AM EDT - 9 months ago

Aligos Therapeutics Receives USAN Council Approval for pevifoscorvir sodium as Nonproprietary Name for ALG-000184

Oct 14, 2025, 8:30 AM EDT - 9 months ago

Aligos Therapeutics to Present at the H.C. Wainwright Liver Disease Conference

Oct 7, 2025, 8:30 AM EDT - 9 months ago

Aligos Therapeutics Announces Eight Abstracts Accepted at The Liver Meeting® 2025

Sep 5, 2025, 7:00 AM EDT - 10 months ago

Aligos Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 4:05 PM EDT - 10 months ago

Aligos Therapeutics Announces Six Preclinical Presentations at the 2025 International HBV Meeting

Sep 2, 2025, 4:05 PM EDT - 10 months ago

Aligos Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 20, 2025, 8:30 AM EDT - 11 months ago

Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Ramón Polo as Senior Vice President, Head of Global Regulatory Affairs

Aug 13, 2025, 8:30 AM EDT - 11 months ago

Aligos Therapeutics Announces First Subject Dosed in the Phase 2 B-SUPREME Study of ALG-000184 in Subjects with Chronic HBV Infection

Aug 6, 2025, 4:05 PM EDT - 11 months ago

Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results

Aug 6, 2025, 4:00 PM EDT - 11 months ago

Aligos Therapeutics Quarterly report: Q2 2025

Aug 6, 2025, 4:00 PM EDT - 11 months ago

Aligos Therapeutics Earnings release: Q2 2025

Jul 30, 2025, 4:05 PM EDT - 1 year ago

Aligos Therapeutics to Announce 2nd Quarter 2025 Financial Results on August 6, 2025

Jun 18, 2025, 8:00 AM EDT - 1 year ago

Aligos Therapeutics Appoints Kieron Wesson as Vice President, Head of Chemistry Manufacturing Controls (CMC)

Jun 5, 2025, 2:00 PM EDT - 1 year ago

Aligos Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

May 29, 2025, 8:00 AM EDT - 1 year ago

Aligos Therapeutics to Present at the Jefferies Global Healthcare Conference

May 20, 2025, 8:00 AM EDT - 1 year ago

Aligos Therapeutics Appoints Laura Kavanaugh as Vice President, Head of Legal

May 8, 2025, 8:00 AM EDT - 1 year ago

Aligos Therapeutics Presents Positive Data at the EASL Congress 2025

May 6, 2025, 9:30 AM EDT - 1 year ago

Aligos Therapeutics Quarterly report: Q1 2025

May 6, 2025, 9:30 AM EDT - 1 year ago

Aligos Therapeutics Earnings release: Q1 2025

May 6, 2025, 8:00 AM EDT - 1 year ago

Aligos Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial Results

Apr 29, 2025, 8:30 AM EDT - 1 year ago

Aligos Therapeutics to Announce 1st Quarter 2025 Financial Results on May 6, 2025

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Aligos Therapeutics Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Aligos Therapeutics Proxy statement: Proxy Filing

Apr 23, 2025, 4:05 PM EDT - 1 year ago

Aligos Therapeutics Announces Eight Abstracts Accepted for Presentation at the EASL Congress 2025

Apr 16, 2025, 8:00 AM EDT - 1 year ago

Aligos Therapeutics Proxy statement: Proxy Filing

Mar 27, 2025, 8:00 AM EDT - 1 year ago

Aligos Therapeutics Registration statement: Registration Filing

Mar 26, 2025, 8:00 AM EDT - 1 year ago

Aligos Therapeutics Presents Positive Data at APASL 2025

Mar 10, 2025, 9:30 AM EDT - 1 year ago

Aligos Therapeutics Annual report: Q4 2024

Mar 10, 2025, 9:30 AM EDT - 1 year ago

Aligos Therapeutics Earnings release: Q4 2024

Mar 10, 2025, 8:00 AM EDT - 1 year ago

Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results

Mar 3, 2025, 8:00 AM EST - 1 year ago

Aligos Therapeutics to Announce 4th Quarter 2024 Financial Results on March 10, 2025

Feb 12, 2025, 7:00 AM EST - 1 year ago

Aligos Therapeutics Announces $105 Million Private Placement Financing

Dec 3, 2024, 4:15 PM EST - 1 year ago

Aligos Therapeutics Transcript: 7th Annual Evercore ISI HealthCONx Healthcare Conference

Dec 3, 2024, 11:00 AM EST - 1 year ago

Aligos Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 19, 2024, 1:30 PM EST - 1 year ago

Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024

Nov 6, 2024, 4:05 PM EST - 1 year ago

Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results

Nov 6, 2024, 4:00 PM EST - 1 year ago

Aligos Therapeutics Quarterly report: Q3 2024

Nov 6, 2024, 4:00 PM EST - 1 year ago

Aligos Therapeutics Earnings release: Q3 2024

Nov 6, 2024, 7:00 AM EST - 1 year ago

Aligos Therapeutics Registration statement: Registration Filing

Oct 8, 2024, 3:00 PM EDT - 1 year ago

Aligos Therapeutics Transcript: 8th Annual MASH Investor Conference

Oct 1, 2024, 8:00 AM EDT - 1 year ago

Aligos Therapeutics Appoints David Perry as Vice President of Business Development

Sep 30, 2024, 8:00 AM EDT - 1 year ago

Aligos Therapeutics to Present at Investor Conferences in October

Sep 19, 2024, 8:30 AM EDT - 1 year ago

Aligos Therapeutics Transcript: Study Result

Sep 19, 2024, 8:30 AM EDT - 1 year ago

Aligos Therapeutics Press release: Study Result

Sep 19, 2024, 8:30 AM EDT - 1 year ago

Aligos Therapeutics Slides: Study Result

Sep 19, 2024, 8:00 AM EDT - 1 year ago

Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH

Sep 18, 2024, 5:00 PM EDT - 1 year ago

Aligos Therapeutics to Announce Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024

Aug 15, 2024, 9:00 AM EDT - 2 years ago

Aligos Therapeutics Announces Reverse Stock Split

Aug 8, 2024, 4:05 PM EDT - 2 years ago

Aligos Therapeutics Strengthens Board with Two New Independent Directors

Aug 6, 2024, 4:00 PM EDT - 2 years ago

Aligos Therapeutics Quarterly report: Q2 2024

Aug 6, 2024, 4:00 PM EDT - 2 years ago

Aligos Therapeutics Earnings release: Q2 2024

Jul 22, 2024, 9:00 AM EDT - 2 years ago

Aligos Therapeutics Announces Clinical Collaboration with Xiamen Amoytop Biotech Co., Ltd.

Jul 10, 2024, 8:00 AM EDT - 2 years ago

Aligos Therapeutics to Host KOL Event to Discuss the Positive Phase 1b Data from ALG-000184 for the Treatment of CHB

Jun 5, 2024, 2:30 AM EDT - 2 years ago

Aligos Therapeutics Presents Positive Data at the EASL Congress 2024

May 22, 2024, 4:05 PM EDT - 2 years ago

Aligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024

May 21, 2024, 8:00 AM EDT - 2 years ago

Aligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2a HERALD Study for the Treatment of MASH

May 7, 2024, 4:00 PM EDT - 2 years ago

Aligos Therapeutics Quarterly report: Q1 2024

May 7, 2024, 4:00 PM EDT - 2 years ago

Aligos Therapeutics Earnings release: Q1 2024

Apr 30, 2024, 4:05 PM EDT - 2 years ago

Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024

ALGSmoon Jun. 29 at 6:16 PM

$ALGS gotta make sure management is taken care of. Big salaries and more stock while this probably goes all time lows in the next 60 days.

1 · Reply

ALGSmoon Jun. 26 at 1:02 AM

0 · Reply

Buyhighsellatlow Jun. 17 at 7:49 PM

$ALGS guys, is this the pump before the dilution? Asking for a friend.

1 · Reply

CrazyStockup Jun. 16 at 4:26 PM

$ALGS What’s going on here …. ! Can’t wait for a PR which makes this move UP North !!!

0 · Reply

RocketCityRetai1 Jun. 16 at 2:04 AM

$ALGS they need to hurry up with the dilution. I want to buy before EOP2

0 · Reply

ALGSmoon Jun. 12 at 11:11 PM

0 · Reply

10PieceTeriyaki Jun. 10 at 12:19 AM

$ALGS under 4$ no proublem here i am saying this again

0 · Reply

ALGSmoon Jun. 9 at 7:39 PM

$ALGS something is brewing. Almost out of shares to short and the stock is up 5%

0 · Reply

ALGSmoon Jun. 9 at 5:56 AM

0 · Reply

ALGSmoon Jun. 8 at 11:35 PM

$ALGS

0 · Reply

HedgeUrHedge Jun. 6 at 5:26 PM

$ALGS Can we at least wait till they release top line results before trying to destroy the company.

1 · Reply

ALGSmoon Jun. 6 at 2:35 AM

$ALGS would love to hear the company talk about their MASH drug with this coming soon. Is this why Hep-b is ths focus now? https://pmc.ncbi.nlm.nih.gov/articles/PMC12190491/

0 · Reply

ALGSmoon Jun. 5 at 5:51 PM

$ALGS so short shares available is sitting at a historically quasi-bullish level. And order flow today definitely flipped bullish. Still early but can we trust this?

0 · Reply

Suppandi Jun. 4 at 6:21 PM

$ALGS Not sure what us going on with this company. Are people getting sick using this medicine. Why is this stock not going up

2 · Reply

ALGSmoon Jun. 4 at 5:38 PM

$ALGS short interest at 12 month high.

0 · Reply

ALGSmoon Jun. 4 at 3:03 PM

$ALGS and the shorts win again

0 · Reply

ALGSmoon Jun. 4 at 2:18 PM

$ALGS bid woke up!

1 · Reply

ALGSmoon Jun. 3 at 3:46 PM

$ALGS deer in headlights just waiting to die.

0 · Reply

ALGSmoon Jun. 2 at 7:35 PM

$ALGS algos see the weak book and short every time someone hits the ask. Easy money for them with basically no risk.

0 · Reply

ALGSmoon Jun. 2 at 2:25 PM

$ALGS new 52 week low with market at ATH. NICE.

1 · Reply

ALGSmoon May. 29 at 2:45 AM

$ALGS this is very sus. It’s going up with red candles everywhere and the order flow is very negative. Really feels like a someone is building a short position in advance of something happening.

0 · Reply

ALGSmoon May. 27 at 9:38 PM

$ALGS they may not even pump it before the offering. They may just drop it on us here.

0 · Reply

Market Cap	34.59M
Revenue (ttm)	2.19M
Net Income (ttm)	-24.19M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,104.57%
Debt to Equity Ratio	0.00

Volume	90,300
Avg Vol	115,078
Day's Range	N/A - N/A
Shares Out	6.19M
Stochastic %K	49%
Beta	2.26
Analysts	Strong Sell
Price Target	$56.28